ARTELO BIOSCIENCES INC C/WTS 25/06/2024(TO PUR COM) ARTLW 深 滬
等待開盤 01-28 09:30:00 美东时间
0.0056
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0056
- 總市值 1.87万
- 52周最高 0.1498
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.005
- 委 比 0.00%
- 總股本 334.74万
- 歷史最高 1.25
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.005
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Artelo Biosciences faces new Nasdaq compliance challenges
Artelo Biosciences ( ($ARTL) ) just unveiled an announcement. Artelo Bioscience...
01-17 06:52
Artelo Biosciences Plans Clinical Development Of ART12.11 CBD Therapy Following White House Medicare Pilot Executive Order
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain,
2025-12-23 22:05
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Clene (NASDAQ:CLNN) stock increased by 10.0% to $7.94 during Wednesday'...
2025-12-04 05:06
Maxim Group Downgrades Artelo Biosciences to Hold
Maxim Group analyst Jason McCarthy downgrades Artelo Biosciences (NASDAQ:ARTL) from Buy to Hold.
2025-11-19 23:48
Artelo Biosciences GAAP EPS of $3.97
Artelo Biosciences press release (ARTL): Q3 GAAP EPS of $3.97. In September 2025, the Company completed a confidentially marketed public offering of common stock with gross proceeds of $3.0 million. ...
2025-11-12 22:28
Artelo Biosciences Q3 EPS $(3.97) Misses $(0.82) Estimate
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(3.97) per share which missed the analyst consensus estimate of $(0.82) by 384.15 percent. This is a 89.05 percent decrease over losses of $(2.10) per share
2025-11-12 21:28
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results
Artelo Biosciences reported positive interim Phase 2 results for ART27.13 in treating cancer anorexia cachexia syndrome, showing significant weight gain and safety. ART26.12 is advancing toward a multiple ascending dose study, with growing interest from pharmaceutical partners. ART12.11’s first-in-human trial is expected to begin in early 2026. The company’s Q3 2025 financials showed R&D expenses of $1.3M and a net loss of $3.1M, with $1.7M in ca...
2025-11-12 13:00
Artelo Biosciences Announces Publication Of Peer-Reviewed Article, "The Emerging Role Of Fatty Acid Binding Protein 3 (FABP3) In Cancers", In Drug Discovery Today
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological
2025-11-04 21:34
Artelo Biosciences Appoints Mark Spring CFO, Effective Nov. 1
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological
2025-10-27 20:01
Artelo Biosciences Enters Cooperation Agreement with Farb
An update from Artelo Biosciences ( ($ARTL) ) is now available. On October 15, ...
2025-10-18 05:03
